New long-acting beta agonist for nebulizer approved
Formoterol fumarate (Perforomist Inhalation Solution, Dey L.P.), a long-acting beta2-agonist (LABA), has been approved by the FDA as a twice-daily maintenance treatment of bronchoconstriction for chronic bronchitis and emphysema, or COPD.
Formoterol fumarate (Perforomist Inhalation Solution, Dey L.P.), a long-acting beta2-agonist (LABA), has been approved by the FDA as a twice-daily maintenance treatment of bronchoconstriction for chronic bronchitis and emphysema, or COPD. According to the manufacturer, the new solution is the first formoterol product to be approved for use in a nebulizer and is available in a 20 mcg/2 ml concentration. The prescribing information warns pharmacists that LABAs should not be used to treat acute symptoms or patients with rapidly deteriorating COPD; acute symptoms should be treated with fast-acting rescue inhalers. Formoterol fumarate was previously approved as an inhalation powder and is available as Foradil Aerolizer from Schering-Plough.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
